



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RECEIVED

Li et al.

Art Unit:

MAR 0 2 2004

Appl. No.: 09/518,381

Examiner:

Filed: March 3, 2000

Confirmation No.: 5756

1646

Basi, N.

Atty. Docket: 1488.1220002/EKS/PAJ

For: Human G-Protein Coupled

Receptors

First Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(c)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on June 9, 2000 in connection with the above-captioned application. Copies of the documents are provided.

The Examiner's attention is directed to the following co-pending U.S. patent applications:

U.S. Application No. 09/518,383, Li et al., filed March 3, 2000 and submitted herewith as document AR8; and

U.S. Application No. 09/827,937, Li et al., filed April 9, 2001, published now as U.S. Published Application No. 2002/0052043 A1 and submitted herewith as document AE1;

which are directed to related technical subject matter. The identification of these U.S. patent applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the

merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

Documents AN1, AO1, and AS7 were cited in a European search report (Document AT7) by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman Attorney for Applicants Registration No. 45,986

Date: Fif: 24,200

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

OLE &			_						Page 1 of 5
	/غ				ATTY. DOCKET			PLICATION NO	
REB 2 % 2004	岁	EODM E	PTO-1449		1488.1220002/EI		09	/518,381	
PER .	<i>Ę</i>)	FORIVI F	10-1449		FIRST NAMED INV	ENTOR			
FIRST SUE	PLEMEN			DISCLOSURE	FILING DATE	· · - · - ·		T UNIT	
FIRST SUR	· · · · · · · · · · · · · · · · · · ·	STATE	<u>EMENT</u>	11.C. D.A	March 3, 2000	ITO	16	46	
EXAMINER		TDOC	JMENT	U.S. PA	TENT DOCUMEN	115	· · · · · · · · · · · · · · · · · · ·		T
INITIAL		NUME		DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA1								
	AB1					DEC	P1) /P-		
	AC1					DEC	EIVE	}	
	AD1	 	<u> </u>			MAR	0 2 2004	<u> </u>	
			100=0010.4.4	25/20/202			0 2 2004		
	AE1	2002	/0052043 A1	05/02/2002	Li et al.				04/09/2001
	AF1								
	AG1								
	AH1								
	Al1								
	AJ1	<u> </u>							
	AK1	-							
	į			FOREICN	PATENT DOCUM	ENTS	<u> </u>		
EXAMINER		DOC	UMENT	FOREIGN	PATENT DOCUM	ENIS	1	_	
INITIAL		NUM		DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL1	ı							Yes No
	7,21	-							Yes
	AM1			·					No
	AN1	wo	91/15583 A1	10/17/1991	WIPO				Yes No
									Yes
	AO1	<u> wo</u>	99/35106 A2	07/15/1999	WIPO				No Yes
	AP1								No.
	1		OTHER (Ir	ncluding Auth	or, Title, Date, Pe	rtinent Pa	iges, etc.)		
	AR								
	AS	Birkenbach, M., et al., "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," <i>J. Virol.</i> 67:2209-2220, American Society for Microbiology (1993)							
	AT	4	Chattaraj, S. (February 20		straZeneca," Curr. (Opin. Invest	. Drugs 2:25	0-255, Pharma	aPress Ltd.
EXAMINER		I	<u> </u>				DATE	ONSIDERED	
EXAMINER: Ini	tial if refer	ence coi	nsidered, wheth	er or not citation is	s in conformance with N	MPEP 609. I	Draw line thro	ugh citation if no	t in conformance
and not conside	red. Inclu	de copy	of this form with	next communicat	tion to Applicant.				

616	· · · · · · · · · · · · · · · · · · ·	Dona 0 of 5
012		Page 2 of 5
8	ATTY. DOCKET NO. 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381
FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FIRST NAMED INVENTOR Li et al.	
名 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT
STATEMENT	March 3, 2000	1646

PADEMARK										
				U.S.	PATENT DOCUMEN	ITS				
EXAMINER INITIAL			CUMENT MBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE	
	AA AB	-		ļ.,						
	AC	┼—				 				
	AD	-					TEIVE!			
	AE	 				HE	CEIVE	<u> </u>		
	AF	+					R 0 2 200	Ţ		
	AG	+		 			1 4 1	- 3 8		
	AH			-						
	Al	_		-						
	AJ	-								
	AK				-					
				FOREIG	IN PATENT DOCUM	FNTS	<u> </u>	<u> </u>		
EXAMINER INITIAL			OCUMENT JMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION	
	AL		1910-1						Yes No	
	AM						<u> </u>		Yes No	
	AN								Yes No	
	AO								Yes No	
	AP								Yes No	
			OTHER (Including Au	ithor, Title, Date, Pei	rtinent P	ages, etc.)	·		
	AR	<u>5</u>		<.P. and De Wit 4, Elsevier Scier	tt, L.D., "Neurologic Con nce Inc. (1994)	nplications	s of Infectiou	s Mononucleos	is," Ped. Neurol.	
	AS	<u>5</u>	Antigen 1 (I	Grässer, F.A., et al., "Monoclonal Antibodies Directed Against the Epstein-Barr Virus-Encoded Nuclear Antigen 1 (EBNA1): Immunohistologic Detection of EBNA1 in the Malignant Cells of Hodgkin's Disease," <i>Blood 84</i> :3792-3798, The American Society for Hematology (1994)						
	АТ	<u>5</u>	Hollopeter, Nature 409	G., <i>et al.</i> , "Iden):202-207, Natu	ntification of the platelet are Publishing Group (Ja	ADP rece anuary 200	ptor targeted	by antithromb	otic drugs,"	
EXAMINER		<u></u>					DATE	CONSIDERED		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

71	OOCKET NO. APPLICATION NO. 09/518.381
1 100.72	20002/EKS/PAJ 09/518,381
Li et al.	AMED INVENTOR
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE FILING D.	DATE ART UNIT
STATEMENT March 3, 3	2000 1646

EXA 1 412 : = =		DCC:	10.450.5	0.3.	PATENT DOCUMEN	-	1	1		
EXAMINER INITIAL		NUME	JMENT BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA									
	АВ					REC	EIVED			
	AC						0 2 2004			
	AD						0 g 2001			
	AE									
	AF									
	AG									
	AH									
	Al									
	AJ									
	AK									
XAMINER			UMENT	FOREI	GN PATENT DOCUM	ENTS	·			
NITIAL			MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL							Ye N		
	АМ							Ye N		
	AN							Ye N		
	AO							Ye N		
	AP							Ye		
- : - :	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)									
Kikuta, H., et al., "Detection of Epstein-Barr virus DNA in cardiac and aortic tissue Epstein-Barr virus infection associated with Kawasaki disease-like coronary arte 123:90-92, Mosby-Year Book, Inc. (1993)										
	AS	6		Encoded on H		d Mouse EBI1, a Lymphoid-Specific G-Protein-Coupled q12-q21.2," <i>Genomics 23</i> :643-650, Academic Press,				
	AT	<u>6</u>	Tyson, A.A., Jr., et al., "Acute Epstein-Barr Virus Myocarditis Simulating Myocardial Infarction With Cardiogenic Shock," South. Med. J. 82:1184-1187, Southern Medical Association (1989)							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

/	OIPE			
/	<u> </u>		Page 4	of 5
	FEB 2 & 2004 W	ATTY. DOCKET NO. 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381	
· ·	FORM PTO-1449	FIRST NAMED INVENTOR Li et al.		
1		FILING DATE	ART UNIT	
	STATEMENT	March 3, 2000	1646	

				U.S.	PATENT DOCUM	ENTS			_
EXAMINER INITIAL		DOC	JMENT BER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA								
	AB								
	AC					Dr			
	AD					<i>U</i> 1	CEIVE	D	
	AE		•			MA	CEIVE R 0 2 200	4	
	AF							_	
	AG								
	AH		<u></u>						
	Al								
	AJ								
	AK					•			
		<u></u>		FOREI	ON PATENT DOCL	JMENTS			
EXAMINER INITIAL			CUMENT MBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	АМ								Yes No
	AN								Yes No
	AO							-	Yes No
	AP								Yes No
			OTHER	(Including A	uthor, Title, Date,	Pertinent P	ages, etc.)		
	AR	Z	Wang, K., et al., "Blockade of the Platelet P2Y ₁₂ Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model," <i>Arterioscler. Thromb. Vasc. Biol</i> 22:357-362, Lippincott, Williams & Wilkins (February 2003) Database EMBL, Accession No. AA254425, Marra, M., et al., (first available March 1997) Partial European Search Report for European Application No. 03 01 5456, mailed December 17, 2003, European Patent Office, Netherlands						
	AS	7							
	AT	7							
EXAMINER							DATE (CONSIDERED	
EXAMINER: Initiation and not conside	tial if refe	rence co	nsidered, who	ether or not citati	on is in conformance wi	th MPEP 609.	Draw line thro	ugh citation if no	t in conformance

229228_1.DOC

	OIPE A			
J	<u> </u>		Page 5	of:
	7 6 7000h 85	ATTY. DOCKET NO. 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381	
V	FORM PTO-1449	FIRST NAMED INVENTOR Li et al.		
1	K∕XFIRST SURREMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT	
Į	STATEMENT STATEMENT	March 3, 2000	1646	

[U.S. F	PATENT DOCU	MENTS			
EXAMINER INITIAL		DOCU	JMENT BER	DATE	NAME	<u> </u>	CLASS	SUB-CLASS	FILING DATE
	AA					· · ·			
	AB					DECEN			
	AC		<u></u>			RECEN			
	AD		-			MAR 0 2	2004		
	AE								
	AF				-				
	AG	1							
	AH								
	Al								
	AJ								
	AK								
		1		FOREIG	N PATENT DO	CUMENTS	J		
EXAMINER INITIAL			CUMENT MBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL					-			Yes No
	AM					·			Yes No
	AN								Yes No
	AO								Yes No
	AP						-		Yes No
	174		OTHER	Including Au	thor, Title, Dat	e, Pertinent P	ages, etc.)	
	AR	8	Copy of Co 2000 (NOT	o-Pending Non-F PUBLISHED)	Provisional U.S. I	Patent Application	on No. 09/51	8,383, Li <i>et al.</i> ,	filed March 3,
	AS								
	AT								
EXAMINER			1				DATE	CONSIDERED	
					n is in conformance cation to Applicant.		Draw line thr	ough citation if no	t in conformance